P&O Bank

IGC Reports Financial Results for Fiscal Year Ended March 31, 2023

Retrieved on: 
Wednesday, July 12, 2023
Biotechnology, Alternative Medicine, FDA, Health, Cannabis, Pharmaceutical, Mental Health, Natural Resources, Research, Science, Clinical Trials, Epilepsy, Seizure, Commissioner, Human, University, USF, Marketing, Neurotoxicity, Fiscal, Calendar, European Patent Office, Cannabinoid, Amnesia, Composition, Nursing, Dementia, Amyloid, Patent, Patient, Animal, Dog, European Patent Convention, IGC, Medicine, Mouse, Growth, P&O Bank, Health Canada, Death, THC, NYSE, Agitation, Cat, Pharmaceutical industry, CBD

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”).
  • On March 8, 2023, the Company filed a provisional patent application with the USPTO titled “Composition, Synthesis, and Medical Use of Hybrid Cannabinoid”.
  • Ram Mukunda, CEO of IGC, commented, “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug formulations through FDA trials.
  • Net loss for Fiscal 2023 was approximately $11.5 million or $0.22 per share, compared to approximately $15 million or $0.30 per share for Fiscal 2022.

IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

Retrieved on: 
Friday, July 7, 2023
Research, Cannabis, Health Technology, Other Health, Alternative Medicine, Health, Pharmaceutical, Science, Natural Resources, Mukunda, Alzheimer's disease, Calendar, Dementia, Hope, Patient, Bradbury, IGC, NYSE, Agitation, P&O Bank, Pharmaceutical industry

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co., Ltd. (“O-Bank” or the “Bank”).

Key Points: 
  • IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co., Ltd. (“O-Bank” or the “Bank”).
  • Under the terms for the line of credit, IGC can draw up to $1 million within a 30-day period.
  • IGC Pharma’s research and development efforts are focused on Alzheimer’s disease, with three molecules in various stages of development.
  • Ram Mukunda, CEO of IGC Pharma, expressed gratitude for the line of credit provided by O-Bank and the continued support from Bradbury.

X-PITCH 2021 Global Winners Announced

Retrieved on: 
Sunday, November 14, 2021
Semiconductor, Automotive Manufacturing, Security, Manufacturing, Audio, Video, Aftermarket, Automotive, Telecommunications, Software, Networks, Internet, Hardware, Data Management, Consumer Electronics, Technology, Mobile, Wireless, Alternative Vehicles, Fuels, General Automotive, Performance & Special Interest, PITCH, Dayta, Yulon, Silicon, ROC, Transport, Partner, P&O Bank, Founder, BIP Investment Partners, Grand Finale, Year, CIS, Economic development, Ecosystem, CEO, Department, Elan Media Partners, Commerce, Multimedia, ASUS, Founder CEO, Taoyuan City Government, E27, Department of Economic Development, ITRI, New Normal, VC, JETRO, Investment, Overseas Community Affairs Council, Drag Race Holland, BSSC, Creativity, US, Cassette tape, Cryptocurrency, Video game

The TECH FOR GOOD theme of X-PITCH 2021 highlights the challenges in the post-pandemic world, participating teams focus on applications and services that enable digital transformation around five major categories of the New Normal.

Key Points: 
  • The TECH FOR GOOD theme of X-PITCH 2021 highlights the challenges in the post-pandemic world, participating teams focus on applications and services that enable digital transformation around five major categories of the New Normal.
  • 10 startups emerged as winners at the Grand Finale, and the top three startups will receive US$1 million investment in total.
  • X-PITCH is also a platform for global startups, investors, corporates, and ecosystem builders to connect with each other.
  • At the event, Kevin Yu and managing partners James Ku, Brent Hu and Jason Liu announced the official launch of a new VC accelerator firm XCEL NEXT ( www.xcelnext.vc ).